Skip Navigation
Get the latest news

Dr. Michael J. Birrer Explores Molecular, Genetic, and Quality-of-Life Markers Among Long-Term Survivors of Ovarian Cancer

  • ASCO Connection

Each year, 23,000 women in the United States are diagnosed with ovarian cancer, and although the cancer responds to chemotherapy, most patients experience relapse and die from the disease. However, 15% of patients with stage III disease and 5% to 7% of patients with stage IV disease live 8 years or longer. Are there biologic or quality-of-life (QOL) markers that differentiate these patients who survive long term from those who do not?

Read more

Rivkin Center Celebrating 20th Anniversary

  • Press Release

The Marsha Rivkin Center for Ovarian Cancer Research is celebrating its 20th Anniversary in 2016. To celebrate this milestone, the organization is changing its name to the Rivkin Center for Ovarian Cancer.

Read more

Research Explains Limits of Cancer Immunotherapy Drugs

  • University of Michigan Health System

Research from Rivkin Center Scientific Advisory Board member Dr. Weiping Zou MD, PhD published in the journal Nature reveals molecular changes within the tumor that are preventing immunotherapy drugs from killing off cancer.

Read more

Why Groundbreaking New Cancer Drugs Still Don’t Work for Most Patients

  • The Washington Post

Tumors with a high concentration of “T cells,” a type of white blood cell, were more responsive to treatment, whereas tumors with a low number of T cells were far less responsive. The Rivkin Center funded scientist Ilona Kryczek, PhD to work on the mouse models of ovarian cancer cells used in this study

Read more

Hormone Therapy May Improve Ovarian Cancer Survival

  • Cancer Network

According to results of a study published in the Journal of Clinical Oncology, hormone therapy was safely administered in women with severe menopausal symptoms and may have a beneficial effect on survival.

Read more

Challenge Grant Award

Scientist in lab

Pilot Study Deadline Submission

This grant competition is open September 1 – December 1, 2016. To be eligible, initial applications must be received by December 1, 2016 (5pm PT).

Apply Now

Grant award recipient authored publications published by top scientific journals: 55%